ArticleCardiology2010
Pre-clinical myocardial metabolic alterations in chronic kidney disease.
Article in Cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cardiovascular-kidney-metabolic syndrome as a mitochondrial systems disorder.Nature reviews. Nephrology · 2026Review
- PET-Derived Renal Perfusion Provides a Window Into Cardiorenal Risk Beyond Filtration.Circulation. Cardiovascular imaging · 2026Article
- Total-body positron emission tomography: Investigating mechanisms in cardiovascular-kidney-metabolic syndrome.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025Review
- Correlation between Kidney Uptake at [18F]FDG PET/CT and Renal Function.Journal of personalized medicine · 2023Article
- The Cardiorenal Axis: Myocardial Perfusion, Metabolism, and Innervation.Current cardiology reports · 2019Review
- Cardiac molecular imaging to track left ventricular remodeling in heart failure.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Review
- Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls.American journal of nuclear medicine and molecular imaging · 2015Article
- Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.European journal of nuclear medicine and molecular imaging · 2014Review
- Targeted metabolic imaging to improve the management of heart disease.JACC. Cardiovascular imaging · 2012Review
- Metabolic imaging for identifying antecedent myocardial ischemia and acute coronary syndrome in the emergency department.Current cardiology reports · 2011Article
- Fatty acid imaging of the heart.Current cardiology reports · 2011Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
unlabelledThe risk for cardiovascular events conferred by decreased renal function is curvilinear with exponentially greater increases in risk as estimated glomerular filtration rate (eGFR) declines. In 13 non-diabetic pre-dialysis chronic kidney disease (CKD) patients, we employed quantitative F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) as a means to measure myocardial metabolic changes.
methodsDynamic cardiac FDG PET images were acquired after 6 h fasting and glucose loading. Corrections for attenuation, scatter, randoms, dead time and decay were applied to the PET data and myocardial glucose utilization (MGU) was calculated using the Patlak method in conjunction with standardized myocardial regions of interest and an image-derived input function (left atrium). MGU was compared with eGFR based on a serum creatinine drawn within 2 weeks of the study date.
resultsMGU was relatively uniform between the myocardial sectors (coefficient of variation = 16.2 +/- 6.8%) within each patient. Between patients, whole myocardium MGU varied considerably with a range of 37.3-156.2 micromol/min/100 g and a mean of 68.9 +/- 38.3 mumol/min/ 100 g. eGFR ranged from 11-89 ml/min/1.73 m(2) with a mean of 42.8 +/- 26.9 ml/min/1.73 m(2). There was an inverse correlation between whole myocardium MGU and eGFR (Spearman's rho correlation = -0.615, p = 0.025). In multivariate analysis, the relationship between MGU and eGFR was sustained with adjustment for age, race and gender (adjusted beta = -1.56 +/- 0.48, p = 0.01). There was no correlation between cardiac workload and eGFR (p = NS).
conclusionsA significant inverse correlation between MGU and eGFR is supportive of the hypothesis that CKD is associated with myocardial metabolic changes, which could not be attributed to demographic factors or cardiac workload. Dynamic FDG PET could provide a sensitive, non-invasive, quantitative tool for investigating pre-clinical myocardial abnormalities in patients with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.